Original language | English (US) |
---|---|
Pages (from-to) | 950-953 |
Number of pages | 4 |
Journal | Annals of Oncology |
Volume | 32 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2021 |
ASJC Scopus subject areas
- Hematology
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Oncology, Vol. 32, No. 8, 08.2021, p. 950-953.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Bringing safe and effective therapies to premenopausal women with breast cancer
T2 - efforts to broaden eligibility criteria
AU - Gao, J. J.
AU - Krol, D.
AU - Narayan, P.
AU - Cardoso, F.
AU - Regan, M. M.
AU - Goetz, M. P.
AU - Hurvitz, S. A.
AU - Mauro, L.
AU - Hodgdon, C.
AU - Miller, C. P.
AU - Booth, B.
AU - Bloomquist, E.
AU - Ison, G.
AU - Osgood, C.
AU - Bhatnagar, V.
AU - Fashoyin-Aje, L.
AU - Pazdur, R.
AU - Amiri-Kordestani, L.
AU - Beaver, J. A.
N1 - Funding Information: FC: consulting/advisory for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline (GSK), Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seattle Genetics, Teva. MMR: research resources (to institution) for clinical trials from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer; consulting or advisory role (personal) to Bristol-Myers Squibb, Tolmar Pharmaceuticals; honoraria from WebMD. MPG: reports consulting fees (all to institution) from Eagle Pharmaceuticals, Eli Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, and Biotheranostics. Research funding from the National Cancer Institute, National Institutes of Health, Department of Defense, Mayo Development, Eli Lilly, Pfizer, Alliance Foundation Trials, Sermonix Pharmaceutical, Translational Breast Cancer Research Consortium, and Minnesota Partnership for Biotechnology and Medical Genomics. SH: contracted research (to institution): Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd. Travel: Lilly (2019). LM: research resources (to institution) for clinical trials from AstraZeneca, Eli Lilly and Company, Hoffman-La Roche, Pfizer, Radius Pharmaceuticals; consulting or advisory role (personal) to BioTheranostics. CH: Roche/Genentech (honoraria, consulting/advisory), Pfizer (consulting/advisory), Johns Hopkins Hospital (consulting/advisory), NIH/NCI Cancer Moonshot (consulting/advisory), Eli Lilly (travel, accommodations, expenses). All other authors have declared no conflicts of interest. Funding Information: None declared. FC: consulting/advisory for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline (GSK), Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seattle Genetics, Teva. MMR: research resources (to institution) for clinical trials from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer; consulting or advisory role (personal) to Bristol-Myers Squibb, Tolmar Pharmaceuticals; honoraria from WebMD. MPG: reports consulting fees (all to institution) from Eagle Pharmaceuticals, Eli Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, and Biotheranostics. Research funding from the National Cancer Institute, National Institutes of Health, Department of Defense, Mayo Development, Eli Lilly, Pfizer, Alliance Foundation Trials, Sermonix Pharmaceutical, Translational Breast Cancer Research Consortium, and Minnesota Partnership for Biotechnology and Medical Genomics. SH: contracted research (to institution): Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd. Travel: Lilly (2019). LM: research resources (to institution) for clinical trials from AstraZeneca, Eli Lilly and Company, Hoffman-La Roche, Pfizer, Radius Pharmaceuticals; consulting or advisory role (personal) to BioTheranostics. CH: Roche/Genentech (honoraria, consulting/advisory), Pfizer (consulting/advisory), Johns Hopkins Hospital (consulting/advisory), NIH/NCI Cancer Moonshot (consulting/advisory), Eli Lilly (travel, accommodations, expenses). All other authors have declared no conflicts of interest.
PY - 2021/8
Y1 - 2021/8
UR - http://www.scopus.com/inward/record.url?scp=85108191772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108191772&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2021.05.356
DO - 10.1016/j.annonc.2021.05.356
M3 - Editorial
C2 - 33991601
AN - SCOPUS:85108191772
SN - 0923-7534
VL - 32
SP - 950
EP - 953
JO - Annals of Oncology
JF - Annals of Oncology
IS - 8
ER -